Quest Diagnostics Incorporated (DGX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Quest Diagnostics Incorporated (DGX) has a cash flow conversion efficiency ratio of 0.060x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($468.00 Million) by net assets ($7.82 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Quest Diagnostics Incorporated for the company's overall valuation and market capitalisation.
Quest Diagnostics Incorporated - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Quest Diagnostics Incorporated's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Quest Diagnostics Incorporated Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Quest Diagnostics Incorporated ranked by their cash flow conversion efficiency. Explore DGX cash to earnings ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PetroChina Company Limited
F:PC6
|
0.065x |
|
Royalty Pharma Plc
NASDAQ:RPRX
|
0.077x |
|
Volkswagen AG
XETRA:VOW
|
0.003x |
|
China State Construction Engineering Corp Ltd
SHG:601668
|
0.033x |
|
VICI Properties Inc
NYSE:VICI
|
0.022x |
|
SUMITOMO EL.IND.ADR
F:SMO1
|
N/A |
|
FirstEnergy Corporation
NYSE:FE
|
0.010x |
|
Baidu Inc
F:B1C
|
0.009x |
Annual Cash Flow Conversion Efficiency for Quest Diagnostics Incorporated (1996–2025)
The table below shows the annual cash flow conversion efficiency of Quest Diagnostics Incorporated from 1996 to 2025. View DGX stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $7.29 Billion | $1.89 Billion | 0.259x | +33.81% |
| 2024-12-31 | $6.90 Billion | $1.33 Billion | 0.193x | -2.40% |
| 2023-12-31 | $6.42 Billion | $1.27 Billion | 0.198x | -30.70% |
| 2022-12-31 | $6.01 Billion | $1.72 Billion | 0.286x | -15.95% |
| 2021-12-31 | $6.56 Billion | $2.23 Billion | 0.340x | +16.96% |
| 2020-12-31 | $6.89 Billion | $2.00 Billion | 0.291x | +34.90% |
| 2019-12-31 | $5.76 Billion | $1.24 Billion | 0.216x | -3.95% |
| 2018-12-31 | $5.34 Billion | $1.20 Billion | 0.225x | -3.78% |
| 2017-12-31 | $5.04 Billion | $1.18 Billion | 0.233x | +3.41% |
| 2016-12-31 | $4.74 Billion | $1.07 Billion | 0.226x | +33.26% |
| 2015-12-31 | $4.78 Billion | $810.00 Million | 0.169x | -21.82% |
| 2014-12-31 | $4.33 Billion | $938.00 Million | 0.217x | +32.00% |
| 2013-12-31 | $3.97 Billion | $652.00 Million | 0.164x | -42.13% |
| 2012-12-31 | $4.19 Billion | $1.19 Billion | 0.284x | +17.65% |
| 2011-12-31 | $3.71 Billion | $895.50 Million | 0.241x | -12.59% |
| 2010-12-31 | $4.05 Billion | $1.12 Billion | 0.276x | +10.91% |
| 2009-12-31 | $4.01 Billion | $997.40 Million | 0.249x | -15.69% |
| 2008-12-31 | $3.60 Billion | $1.06 Billion | 0.295x | +5.76% |
| 2007-12-31 | $3.32 Billion | $926.92 Million | 0.279x | -11.56% |
| 2006-12-31 | $3.02 Billion | $951.90 Million | 0.315x | +2.29% |
| 2005-12-31 | $2.76 Billion | $851.58 Million | 0.308x | -11.69% |
| 2004-12-31 | $2.29 Billion | $798.78 Million | 0.349x | +26.10% |
| 2003-12-31 | $2.39 Billion | $662.80 Million | 0.277x | -17.91% |
| 2002-12-31 | $1.77 Billion | $596.37 Million | 0.337x | -3.30% |
| 2001-12-31 | $1.34 Billion | $465.80 Million | 0.349x | -2.63% |
| 2000-12-31 | $1.03 Billion | $369.45 Million | 0.358x | +23.87% |
| 1999-12-31 | $863.10 Million | $249.50 Million | 0.289x | +16.10% |
| 1998-12-31 | $567.90 Million | $141.40 Million | 0.249x | -23.50% |
| 1997-12-31 | $541.70 Million | $176.30 Million | 0.325x | +298.14% |
| 1996-12-31 | $538.72 Million | $-88.49 Million | -0.164x | -- |
About Quest Diagnostics Incorporated
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagn… Read more